Epitopes functional in neutralization of varicella-zoster virus
- PMID: 1701445
- PMCID: PMC268214
- DOI: 10.1128/jcm.28.11.2500-2506.1990
Epitopes functional in neutralization of varicella-zoster virus
Abstract
By competition neutralization assay using monoclonal antibodies (MAbs) to varicella-zoster virus (VZV) glycoproteins (gps), we attempted to determine the topographical relationship of epitopes which are functional in VZV neutralization. MAbs against gpI interfered moderately to strongly with neutralization of MAbs against gpIII, and one antigenic domain with two distinct epitopes was identified on gpIII. Competition neutralization assays performed with MAbs to gpI revealed at least three distinct antigenic domains: the first contained two complement-dependent neutralizing epitopes; the second contained five complement-dependent neutralizing, overlapping epitopes and one nonneutralizing, nonoverlapping epitope; and the third contained one complement-enhanced neutralizing epitope. Competition neutralization assays performed with MAbs to gpIV showed one antigenic domain with two distinct epitopes which competed with nonneutralizing gpI MAbs. gpII did not interfere with neutralization of gpI, gpIII, or gpIV. Our data suggest that neutralizing and nonneutralizing MAbs can interfere with the action of viral neutralization either by inhibition or by enhancement. This report describes the epitope mapping of VZV gps by a functional biological assay.
Similar articles
-
Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII).Virology. 1986 Mar;149(2):230-41. doi: 10.1016/0042-6822(86)90124-8. Virology. 1986. PMID: 2418586
-
A human monoclonal antibody against varicella-zoster virus glycoprotein III.J Gen Virol. 1991 Sep;72 ( Pt 9):2065-73. doi: 10.1099/0022-1317-72-9-2065. J Gen Virol. 1991. PMID: 1654371
-
Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies.J Virol Methods. 1986 Sep;14(2):177-88. doi: 10.1016/0166-0934(86)90048-0. J Virol Methods. 1986. PMID: 3021804
-
Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S960-3. doi: 10.1093/clind/13.supplement_11.s960. Rev Infect Dis. 1991. PMID: 1664135 Review.
-
Antigenic variance.Curr Top Microbiol Immunol. 1991;169:181-216. doi: 10.1007/978-3-642-76018-1_7. Curr Top Microbiol Immunol. 1991. PMID: 1718665 Review. No abstract available.
Cited by
-
Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.Vaccines (Basel). 2022 Mar 29;10(4):529. doi: 10.3390/vaccines10040529. Vaccines (Basel). 2022. PMID: 35455278 Free PMC article.
-
Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system.J Virol. 1993 Jan;67(1):305-14. doi: 10.1128/JVI.67.1.305-314.1993. J Virol. 1993. PMID: 8380078 Free PMC article.
-
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.J Virol. 1997 Nov;71(11):8279-88. doi: 10.1128/JVI.71.11.8279-8288.1997. J Virol. 1997. PMID: 9343180 Free PMC article.
-
Microbiology laboratory and the management of mother-child varicella-zoster virus infection.World J Virol. 2016 Aug 12;5(3):97-124. doi: 10.5501/wjv.v5.i3.97. World J Virol. 2016. PMID: 27563537 Free PMC article. Review.
-
Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.J Virol. 1997 Sep;71(9):6913-20. doi: 10.1128/JVI.71.9.6913-6920.1997. J Virol. 1997. PMID: 9261418 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources